AMT-101

Phase 2Small molecule

AApplied Molecular Transport

AMT-101 is one of 50 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisActive, not recruiting

PouchitisActive, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

PouchitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Phase 3

1 2

Mounjaro

Eli Lilly

Phase 3

1 3

Pulmicort

SSalix

Phase 3

3 4

Adtralza

LEO Pharma

Phase 3

1 5

Purinethol

SStason

Phase 3

1 6

ABX464

AAbivax S.A.

Phase 3

8 7

TA-650

Tanabe Pharma Corporation

Phase 3

1 8

Simponi

Johnson & Johnson

Preclinical

15 9

Remicade

OOrganon and Co

Preclinical

26 10

Cobitolimod

IInDex Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ulcerative Colitis2 trials

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

Unknown status·AApplied Molecular Transport·Phase 2·NCT04583358·105 enrolled

Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)

Completed·AApplied Molecular Transport·Phase 2·NCT05372939·51 enrolled

Pouchitis1 trial

Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis

Completed·AApplied Molecular Transport·Phase 2·NCT04741087·22 enrolled

Adult1 trial

SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101

Completed·AApplied Molecular Transport·Phase 1·NCT04224857·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AMT-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMT-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMT-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Applied Molecular Transport company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AApplied Molecular Transport

AMT-101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ulcerative Colitis2 trials

Pouchitis1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News